Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Mish's Global Economic Trend Analysis -- Ignore unavailable to you. Want to Upgrade?

To: Bucky Katt who wrote (48228)	3/16/2006 3:48:28 PM
From: mishedlo	Respond to of 116555

Novavax's AIDS vaccine program gets $1M biz.yahoo.com Thursday March 16, 10:37 am ET Novavax Inc. said Thursday it received a commitment for an additional $1 million from the National Institute of Allergy and Infectious Diseases for the company's AIDS vaccine research program. The NIAID, a component of the National Institutes of Health, will fund the third year of the Malvern, Pa., biopharmaceutical company's four-and-a-half year research program. Novavax (NASDAQ: NVAX - News) is developing a novel HIV/AIDS virus-like particle vaccine as part of an NIH integrated preclinical/clinical AIDS vaccine development program comprised of scientists from the University of Alabama at Birmingham, Emory University and Harvard Medical School. All three institutions are collaborating with Novavax to accelerate HIV/AIDS vaccine development. Novavax's virus-like particle vaccines use recombinant DNA technology to produce structures that mimic a virus to produce a protective immune response without the risk of infection or disease. Published March 16, 2006 by the Philadelphia Business Journal